AHIMA article aims to dispel top ICD-10 misconceptions

An article in the new issue of the Journal of AHIMA aims to dispel several misconceptions regarding ICD-10.

In Myths of ICD-10-CM/PCS, author Sue Bowman, MJ, RHIA, CCS, American Health Information Management Association (AHIMA) senior director of coding policy and compliance, uses evidence to address the following mistruths: the idea that replacement of ICD-9-CM is not a necessity; the increase in the number of codes from ICD-9 to ICD-10 increases the difficulty of using the new codeset; and that SNOMED CT or ICD-11 represent viable alternatives to ICD-10-CM/PCS implementation.

“The transition to ICD-10 continues to be inevitable and time sensitive,” said AHIMA CEO Lynne Thomas Gordon, MBA, RHIA, CAE. “As the healthcare industry experiences an additional delay in ICD-10 implementation, now is the ideal time to rebut ICD-10 myths that continue to percolate.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.